South Carolina

Department of Health and Human Services

Post Office Box 8206 Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting August 7, 2013 **MINUTES**

1. **Call to Order**

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, August 7, 2013.

2. Welcome

Deborah Tapley, R.Ph., called the meeting to order and welcomed members, guests, and staff members.

Ms. Tapley opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. **Committee Members Present:**

Thomas Phillips, R.Ph. Deborah Tapley, R.Ph. Tan Platt, MD

Kelly Jones, PharmD, BCPS Gregory Browning, MD Jony Bollinger, MD

James Lindsey, MD Edward Behling, MD

SC DHHS Staff:

Magellan Medicaid Admin: Jim Assey, R.Ph. Lisa Correll, PharmD Janet Giles Lori Ash

Marion Burton, MD Bryan Amick, PharmD, MBA

Byron Roberts, JD

Constance Holloway, JD Dierdre Singleton, JD

4. **Discussion Topics**

A. Committee Meeting Minutes, Wednesday, May 1, 2013.

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

Company	Speaker	Drug/Class
Janssen	Robert Bailey, MD†	Invokana™

[†] Speaker gave his time back to the Committee.

C. <u>Drug Classes for Review</u>

Lisa Correll led the discussion for the following drug classes:

Antifungals, Topical‡

Glucocorticoids, Oral‡

Bladder Relaxants, Antispasmodics

‡New classes

The chart below represents the recommendations from the P & T Committee:

ANTIFUNGALS, TOPICAL		
Preferred	Non-Preferred	
Ciclopirox (cream/soln/susp)	Bensal HP	
Clotrimazole (cream/soln) RX	CNL 8 Kit	
Clotrimazole/Betamethasone (cream/lotion)	Ciclodan (cream/kit)	
Econazole	Ciclopirox (kit/gel/shampoo)	
Ketoconazole (cream/shampoo)	Ertaczo	
Nystatin (cream/ointment)	Exelderm	
Nystatin/Triamcinolone (cream/ointment)	Extina	
	Ketoconazole foam	
	Ketodan (foam/kit)	
	Loprox (gel/shampoo)	
	Lotrisone cream	
	Mentax	
	Naftin (cream/gel)	
	Nizoral shampoo	
	Nystatin powder	
	Oxistat (cream/lotion)	
	Pedipirox-4	
	Pediaderm AF	
	Penlac	
	Vusion	
	Xolegel	

GLUCOCORTICOIDS, ORAL		
Preferred	Non-Preferred	
Budesonide EC	Dexamethasone Elixir	
Cortef [®]	Dexamethasone Intensol	
Cortisone	Dexpak [®]	
Dexamethasone (tab/soln)	Entocort® EC	
Hydrocortisone	Flo-Pred	
Methylprednisolone tab	Medrol tab	
Methylprednisolone tab dose pack	Medrol tab dose pack	
Prednisolone soln	Millipred DP tab dose pack	
Prednisolone Sodium Phosphate	Millipred (tab/soln)	
Prednisone (tab/soln)	Rayos® tablet DR	
Prednisone tab dose pack	Orapred ODT	
Orapred†	Prednisone Intensol	
	Veripred™ 20	
†Covered for children 0 -12 years of age only	Zema-Pak	

BLADDER RELAXANTS, ANTISPASMODICS		
Preferred	Non-Preferred	
Oxybutynin ER	Detrol	
Oxybutynin (tablet/syrup)	Detrol LA®	
Oxytrol® Transdermal	Ditropan XL®	
Toviaz [®]	Enablex [®]	
Vesicare®	Flavoxate	
	Gelnique® Transdermal	
	Mybetriq [®]	
	Sanctura [®]	
	Sanctura XR®	
	Tolteridone	
	Trospium	
	Trospium ER	

5. Old Business

Lisa Correll provided data on bowel prep claims (volume), Methyldopa usage, disclaimer language on Lindane and Flurazepam, claims data on Gabapentin capsules versus tablets, and claims by prescriber type for Antipsychotics (Oral) requested by the P&T Committee during the May 2013 meeting.

6. New Business

Lisa Correll and Bryan Amick discussed Vancocin® and Invokana™. Dr. Amick also presented information on the Value Based Benefit design to the P&T Committee.

7. Resolved Items

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

Antifungals, Topical Glucocorticoids, Oral Bladder Relaxants, Antispasmodics

8. Closing Comments

The next meeting will be held on Wednesday, November 6, 2013, at 4:00 p.m.

9. Adjournment

The meeting adjourned at 6:00 p.m.